Schlieren ZH/Luxembourg – Topadur Pharma is now working together with Oshen Holdings SA. The aim is to further develop TOP-M119 for the treatment of hair loss. The agreement covers development, license and distribution rights for China.
The biopharmaceutical company Topadur Pharma AG in Schlieren and Oshen Holdings SA, based in Luxembourg, have signed a collaboration agreement to develop a topical liquid form of the drug TOP-M119 for the treatment of alopecia. According to the press release, the agreement includes joint development, licensing and commercialization rights for China. The contract includes equity and development costs totaling CHF 15 million.
Androgenic alopecia is the most common form of hair loss in men and women, according to the press release. Around 60 percent of the world's population have problems with hair loss and hair thinning. The global alopecia market, which was estimated at 8.8 billion dollars in 2023, is expected to grow to a market size of more than 16 billion dollars by 2030. This growth will be driven by the ageing population and demographic change.
TOP-M119 is a promising drug candidate with a novel mechanism of action, according to Topadur. Preclinical studies have shown that TOP-M119 is superior to standard treatment, with a much higher potency, faster onset of action and better local tolerability.
"Based on our preclinical data, we believe that TOP-M119 can be a game changer in the treatment of hair loss and the improvement of hair quality. The partnership with Oshen enables us to accelerate the development of TOP-M119 and provide patients with faster access," said Pascal Brenneisen, CEO of Topadur Pharma AG.
Topadur was founded in 2015 and is a member of the Bio-Technopark Schlieren-Zurich. ce/gba